Price as a challenge to the sustainability of the universal access policy to antiretrovirals in SUS: the case of dolutegravir
Authors:
- Luciana de Melo Nunes LopesLLLuciana de Melo Nunes Lopes
- Carolinne Thays ScopelCSCarolinne Thays Scopel
- Ronaldo Campos HallalRHRonaldo Campos Hallal
- Gustavo Luís Meffe AndreoliGAGustavo Luís Meffe Andreoli
- Draurio BarreiraDBDraurio Barreira
- Marcela Vieira FreireMFMarcela Vieira Freire
- Francisco Alisson Paula de FrançaFFFrancisco Alisson Paula de França
Open Access
- 1 January 2026
- journal article
- Published by FapUNIFESP (SciELO) in Ciencia & Saude Coletiva
- Vol. 31 (1)
Abstract
The price of antiretrovirals (ARVs) continues to be a challenge to guarantee universal, comprehensive, and equitable pharmaceutical services. This article aimed to analyze the acquisition of the most widely used ARV in Brazil, comparing national and international prices. Our study conducted a documentary analysis of the history of the national procurement of dolutegravir (DTG) from 2017 to 2023. The price comparison was based on reports from the Clinton Health Access Initiative (CHAI), considering exchange rate and inflation variations. In 2022, generic versions from Farmanguinhos and Lafepe were distributed, but a patent barrier restricted the procurement from Lafepe. A major difference was found between national and international prices, even with the entry of generics into the Brazilian market; in 2023, the price of international generics was almost 12 times lower than that of the national procurement. The DTG case highlights the importance of monitoring prices, patent barriers, and local production, and of becoming familiar with the structure of production costs in order to negotiate fair prices and ensure the sustainability of the national pharmaceutical assistance policy.Keywords
This publication has 13 references indexed in Scilit:
- The risk of sexual transmission of HIV in individuals with low-level HIV viraemia: a systematic reviewThe Lancet, 2023
- Impact on life expectancy of HIV-1 positive individuals of CD4+ cell count and viral load response to antiretroviral therapyAIDS, 2014
- Closing the Gap: Increases in Life Expectancy among Treated HIV-Positive Individuals in the United States and CanadaPLOS ONE, 2013
- Ten‐year mortality trends among persons diagnosed with HIV infection in England and Wales in the era of antiretroviral therapy: AIDS remains a silent killerHIV Medicine, 2013
- Polymorphs and Prodrugs and Salts (Oh My!): An Empirical Analysis of “Secondary” Pharmaceutical PatentsPLOS ONE, 2012
- Driving a decade of change: HIV/AIDS, patents and access to medicines for allJournal of the International AIDS Society, 2011
- Brazilian policy of universal access to AIDS treatment: sustainability challenges and perspectivesAIDS, 2007
- Mortality in the Highly Active Antiretroviral Therapy EraJAIDS Journal of Acquired Immune Deficiency Syndromes, 2006
- Examining the production costs of antiretroviral drugsAIDS, 2006
- Dramatic improvement in survival among adult Brazilian AIDS patientsAIDS, 2003